Elekta AB ser. B (EKTAb)

Currency in SEK
58.05
+0.25(+0.43%)
Closed·
Earnings results expected in 9 days
High dividend Yield
EKTAb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
57.7058.50
52 wk Range
41.8666.70
Key Statistics
Prev. Close
57.8
Open
57.8
Day's Range
57.7-58.5
52 wk Range
41.86-66.7
Volume
942.73K
Average Volume (3m)
1.21M
1-Year Change
9.9432%
Book Value / Share
20.86
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EKTAb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
60.40
Upside
+4.05%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Elekta AB ser. B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
3 Hold
7 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 60.40
(+4.05% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Hold60.00+3.36%49.00Maintain13-03-2026
Goldman Sachs
Sell60.00+3.36%54.00Maintain02-12-2025
UBS
Sell39.00-32.82%34.00Maintain01-12-2025
JPMorgan
Sell61.00+5.08%47.00Maintain27-11-2025
Barclays
Sell46.00-20.76%41.50Maintain27-11-2025

Earnings

Latest Release
05-03-2026
EPS / Forecast
0.88 / 0.44
Revenue / Forecast
4.24B / 4.37B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.10%
Dividend Yield
4.32%
Industry Median 1.93%
Annualised payout
2.40
Paid unevenly
5-Years Growth
+21.67%
Growth Streak

EKTAb Income Statement

Compare EKTAb to Peers and Sector

Metrics to compare
EKTAb
Peers
Sector
Relationship
P/E Ratio
−552.1x21.5x−0.5x
PEG Ratio
5.320.310.00
Price/Book
2.8x2.0x2.6x
Price / LTM Sales
1.3x2.0x3.2x
Upside (Analyst Target)
3.8%71.1%55.3%
Fair Value Upside
Unlock25.6%9.7%Unlock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Employees
4438
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
114.38M29.94%6.35B
Other Institutional Investors
154.04M40.32%8.55B
Public Companies & Retail Investors
113.66M29.75%6.31B
Total
382.08M100.00%21.21B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Fourth Swedish National Pension Fund (AP4)9.15%3,49,64,91020,20,972
T. Rowe Price Group, Inc.5.10%1,94,90,85211,26,571

FAQ

What Is the Elekta B (EKTAb) Share Price Today?

The Elekta B share price today is 58.05.

What is the current Elekta B (EKTAb) share price and day range?

As of 19-05-2026, the Elekta B share price is 58.05, with a previous close of 57.80. The share price has ranged from 57.70 to 58.50 today, while the 52-week range spans from 41.86 to 66.70.

What Is the Elekta B Market Cap?

As of today, Elekta B market cap is 21.51B.

Does Elekta B Pay Dividends? What's The Current Dividend Yield?

The Elekta B dividend yield is 4.26%.

What Is the Elekta B (EKTAb) Share Price Target?

The average 12-month share price target for Elekta B is 60.40, with a high estimate of 100 and a low estimate of 39. 5 analysts recommend buying, while 7 suggest selling, with an overall rating of Neutral and +4.05% Upside potential.

What Is Elekta B's Earnings Per Share (TTM)?

The Elekta B EPS (TTM) is -0.10.

When Is the Next Elekta B Earnings Date?

Elekta B will release its next earnings report on 28-05-2026.

From a Technical Analysis Perspective, Is EKTAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Elekta B Trade On?

Elekta B is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Elekta B?

The stock symbol for Elekta B is "EKTAb."

How Many Times Has Elekta B Stock Split?

Elekta B has split 2 times.

How Many Employees Does Elekta B Have?

Elekta B has 4438 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.